Employing rational novel agent combination therapy to improve transplant cure rates for relapsed/refractory Hodgkin Lymphoma: Difference between revisions
Jump to navigation
Jump to search
wikispore>Pkdilena No edit summary |
m (4 revisions imported: Import Stardit pages from Wikispore.) |
||
| (2 intermediate revisions by 2 users not shown) | |||
| Line 2: | Line 2: | ||
|type_parameter=research | |type_parameter=research | ||
|description_parameter=Hodgkin Lymphoma (HL) is a rare malignancy, with 500 new cases annually in young Australians. While 70 per cent of patients are cured with front line treatment, 30 per cent of patients require second line therapy which often fails resulting in death. Immunotherapy and targeted therapies have dramatically improved survival in haematological malignancies. This study will combine two agents currently approved in recurrent HL to maximise survival of these young Australians. | |description_parameter=Hodgkin Lymphoma (HL) is a rare malignancy, with 500 new cases annually in young Australians. While 70 per cent of patients are cured with front line treatment, 30 per cent of patients require second line therapy which often fails resulting in death. Immunotherapy and targeted therapies have dramatically improved survival in haematological malignancies. This study will combine two agents currently approved in recurrent HL to maximise survival of these young Australians. | ||
|aim_parameter={{aim parameter|maximise survival of | |aim_parameter={{aim parameter|maximise survival of young Australians with Hodgkin Lymphoma}} | ||
|state_parameter=ongoing | |state_parameter=ongoing | ||
|start_date_parameter=2021-01-01 | |start_date_parameter=2021-01-01 | ||
| Line 8: | Line 8: | ||
|location_parameter=Australia | |location_parameter=Australia | ||
|location_link=No | |location_link=No | ||
|URL_parameter=https://www.grants.gov.au/Ga/Show/9d10d108-a60a-443f-90b2-e834774a542b | |||
|author_parameter={{author parameter | |author_parameter={{author parameter | ||
|aut_nam=Portia Dilena | |aut_nam=Portia Dilena | ||
|aut_url=https://scholars.latrobe.edu.au/pdilena | |aut_url=https://scholars.latrobe.edu.au/pdilena | ||
|aut_con=non contact | |||
}}{{author parameter | |||
|aut_nam=Jack Nunn | |||
|aut_url=https://orcid.org/0000-0003-0316-3254 | |||
|aut_tas=Checked STARDIT report data | |||
|aut_con=non contact | |aut_con=non contact | ||
}} | }} | ||
| Line 24: | Line 30: | ||
|inp_inp=1,225,487.40 | |inp_inp=1,225,487.40 | ||
|inp_currency=AUD | |inp_currency=AUD | ||
|inp_url=https://www.grants.gov.au/Ga/Show/9d10d108-a60a-443f-90b2-e834774a542b | |||
}} | }} | ||
}} | }} | ||
Latest revision as of 21:22, 18 November 2023
Description: Hodgkin Lymphoma (HL) is a rare malignancy, with 500 new cases annually in young Australians. While 70 per cent of patients are cured with front line treatment, 30 per cent of patients require second line therapy which often fails resulting in death. Immunotherapy and targeted therapies have dramatically improved survival in haematological malignancies. This study will combine two agents currently approved in recurrent HL to maximise survival of these young Australians.
Dates
State ongoing
Start 2021-01-01
End 2026-01-01
Form updated 2023-11-18
Location
Australia
Aims
maximise survival of young Australians with Hodgkin Lymphoma
Category
research
Inputs
individual
Eliza Hawkes
Task: Lead Chief Investigator
Compensation: paid